BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
TAK upcoming catalysts
Takeda: 7 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 12 readout(s) and 3 FDA event(s). Subscribe to TAK (.ics).
Drugs: TAK-360, Maribavir, Zasocitinib, TAK-279, TAK-788, TAK-861, Teduglutide, Pemetrexed, Cisplatin, Carboplatin, Deucravacitinib, Pembrolizumab, Platinum
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | Takeda TAK | NCT06812078 A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Idiopathic Hypersomnia | recruiting | 96 |
| 2026-11-30 est. | P2 | Takeda TAK | NCT06952699 A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Narcolepsy Type 2 | recruiting | 88 |
| 2026-12-17 est. | P3 | Takeda TAK | NCT07363720 A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | active not recruiting | 98 |
| 2027-01-18 est. | P3 | Takeda TAK | NCT05319353 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in C | Cytomegalovirus (CMV) | recruiting | 80 |
| 2027-02-05 est. | P2 | Takeda TAK | NCT07244263 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 91 |
| 2027-02-10 est. | P3 | Takeda TAK | NCT06973304 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Short Bowel Syndrome | active not recruiting | 13 |
| 2027-02-17 est. | P2 | Takeda TAK | NCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | recruiting | 268 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-08-28 | FDA approval | approved | TAKEDA PHARMS AM TAK | MIMRYLO | Approved 2026-08-28: MIMRYLO (NDA220605 ORIG1) |
| 2026-08-05 | FDA approval | approved | TAKEDA PHARMS USA TAK | ORZEYFUL | Approved 2026-08-05: ORZEYFUL (NDA220860 ORIG1) |
| 2025-11-21 | FDA approval | approved | TAKEDA PHARMS USA TAK | LIVTENCITY | Approved 2025-11-21: LIVTENCITY (NDA215596 SUPPL7) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-29 | P1/P2 | Takeda TAK | NCT02716116 A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | completed | 324 |
| 2026-09-22 | P3 | Takeda TAK | NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | 354 |
| 2026-07-22 | P3 | Takeda TAK | NCT06439342 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Cytomegalovirus (CMV) | completed | 20 |
| 2026-07-21 | P2 | Takeda TAK | NCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old | Gastroesophageal Reflux Disease (GERD) | completed | 71 |
| 2026-07-14 | P2 | Takeda TAK | NCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 213 |
| 2026-06-29 | P3 | Takeda TAK | NCT07047521 A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Dengue Fever | active not recruiting | 496 |
| 2026-04-22 | P3 | Takeda TAK | NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | Plaque Psoriasis | completed | 606 |
| 2026-04-16 | P2 | Takeda TAK | NCT05714969 A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) | Thrombotic Thrombocytopenic Purpura (TTP) | completed | 29 |
| 2026-04-13 | P2 | Takeda TAK | NCT02615184 A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old | Erosive Esophagitis | terminated | 24 |
| 2026-03-30 | P1/P2 | Takeda TAK | NCT04420884 A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Solid Neoplasms | completed | 248 |
| 2026-01-20 | P2/P3 | Takeda TAK | NCT05755035 A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases | Primary Immunodeficiency Diseases (PID) | completed | 65 |
| 2025-12-09 | P2 | Takeda TAK | NCT04530123 Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Fre | Celiac Disease | completed | 102 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.